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We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host
disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and
reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to
validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent
transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. Ac-
cording to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1
(0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only
1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall
survival were signiﬁcantly different between each RG (all P < .01). NRM and overall survival at 5 years after
CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectivelyedgments on page 644.
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M. Arora et al. / Biol Blood Marrow Transplant 21 (2015) 640e645 641(all P < .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM
in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major
outcomes, tailor treatment planning, and enroll patients in clinical trials.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The beneﬁcial antileukemic effect of chronic graft-versus-
host disease (CGVHD) is offset by an increased risk of late
nonrelapse mortality (NRM) [1]. Several clinical risk factors
have been identiﬁed as predictors of outcomes in patients
with CGVHD [2-17]. We previously identiﬁed 10 variables
signiﬁcantly associated with both NRM and survival in 5343
patients with CGVHD who underwent transplantation be-
tween 1995 and 2004 [18]. We then developed a CGVHD
Center for International Blood and Marrow Transplant
Research (CIBMTR) risk score using these variables. Variables
included in the score were age, prior acute graft-versus-host
disease (GVHD), time from hematopoietic stem cell trans-
plantation (HCT) to CGVHD, donor type, disease status at
transplantation, GVHD prophylaxis, gendermismatch, serum
total bilirubin, Karnofsky performance status (KPS), and
platelet count at time of diagnosis of CGVHD. Six risk groups
(RG) were identiﬁed with powerful discriminative ability to
predict NRM and overall survival.
In the current study, we sought to validate this risk score
in an independent dataset of 1128 patients with CGVHD who
underwent transplantation between 2005 and 2007 using
the same inclusion criteria and risk score calculations.
METHODS
The CIBMTR is a research organization formed in 2004 as an afﬁliation of
the International Bone Marrow Transplant Registry, the Autologous Blood
and Marrow Transplant Registry, and the National Marrow Donor Program
(NMDP). The CIBMTR is a voluntary organization involving more than 500
transplantation centers that have collaborated to share patient data and
conduct scientiﬁc studies. The quality and compliance of data submission
aremonitored by computerized checks for errors, physician reviews, and on-
site audits.
Study Population
The study population was selected using similar criteria as reported in
the original cohort [18]. We included all patients who received a ﬁrst allo-
geneic HCT from a related or unrelated donor (URD) including umbilical
cord blood for acute myelogenous leukemia, acute lymphoblastic leukemia,
chronic myelogenous leukemia, or myelodysplastic syndrome between
2005 and 2007; were diagnosed with CGVHD within 1 year of trans-
plantation; and reported to the CIBMTR.
All surviving recipients who received transplantations from URDs
included in this analysis were retrospectively contacted and provided
informed consent for participation in the NMDP research program. Informed
consent for retrospective data analysis was waived by the NMDP institu-
tional review board for all deceased patients. Surviving patients who did not
provide signed informed consent to allow analysis of their clinical data were
excluded. To adjust for potential bias introduced by the exclusion of non-
consenting surviving patients, a corrective action plan modeling process
randomly excluded approximately the same percentage of deceased pa-
tients using a biased coin randomization with exclusion probabilities based
on characteristics associated with not providing consent for use of data in
survivors. The study cohort included a total of 1128 HCT recipients with
CGVHD.
Deﬁnitions
CGVHD was diagnosed according to standard CIBMTR criteria [9,19],
which includes all patients with clinical criteria of CGVHD [19] with or
without positive histology, regardless of time of onset of symptoms. Data
required to generate an National Institutes of Health (NIH) score [20] were
not prospectively collected by the CIBMTR during the study period. We
deﬁned reduced-intensity (RIC)/nonmyeloablative regimens (NMA) based
on standard deﬁnitions [21]. HLA matching was deﬁned based on algorithmdescribed by Weisdorf et al. [22]. Disease stage at HCT was deﬁned as early,
intermediate, or advanced based on predeﬁned criteria [18]. Overall survival
was estimated from onset of CGVHD. Death from any cause was treated as
the event. Surviving patients were censored at the date of last contact. NRM
was deﬁned as death in continuous remission. The event was summarized
by the cumulative incidence estimate with relapse as the competing risk.
Study Endpoints and Statistical Analysis
The primary endpoint of this study was to validate the previous CGVHD
risk categorization [18] for NRM and overall survival using a more recent
cohort of CIBMTR-registered subjects. The score used has been previously
reported and is shown in Supplemental Table 1 [18]. In brief, 10 variables
identiﬁed to be signiﬁcantly associated with overall survival and NRM
(recipient age at transplantation, prior acute GVHD, time to onset of CGVHD,
serum bilirubin at CGVHD onset, KPS at CGVHD onset, presence of throm-
bocytopenia at CGVHD onset, donor type, disease status at transplantation,
GVHD prophylaxis, and gender mismatch) were used to build the risk score.
Each variable was assigned a variable-speciﬁc risk score. Variable-speciﬁc
risk scores were summed for each patient to assign an overall risk score,
which was then categorized into 1 of the risk groups (Table 1 and
Supplemental Table 1). Variables related to patient, disease, and trans-
plantation characteristics were described using descriptive statistics.
Continuous variables were reported as medians with ranges, whereas cat-
egorical variables were reported as absolute numbers and proportions.
Cumulative incidence for NRM was calculated treating disease progression/
relapse as the competing risk [23]. Overall survival was calculated using
Kaplan-Meier estimates, and 95% conﬁdence intervals (CIs) were calculated
using the variance derived from the formula of Greenwood [24]. Time to
event was calculated from the date of diagnosis of CGVHD. We used the log-
rank test to compare the differences between groups in the time-to-event
analysis. All P values were 2 sided. Patient-, disease-, HCT-, and CGVHD-
related variables and the assigned risk group were included in the multi-
variate analyses using a stepwise forward selection technique. P  .01 was
the criteria for inclusion in the ﬁnal models [25].
RESULTS
The study population included 1128 HCT recipients with
CGVHD. Tables 1 and 2 compare the demographic, trans-
plantation, and CGVHD characteristics of the validation
cohort (HCT between 2005 and 2007) to the training cohort
(HCT between 1995 and 2004) [18]. As shown in Table 2,
patients in the validation cohort (2005 to 2007) were older
than those in the training cohort (1995 to 2004), were more
likely to receive their HCT from an HLA-matched sibling or
well-matched/partially matched URD, and have a trans-
plantation for early disease status compared with those in
the training cohort [1]. Cyclosporine (CSA) and
methotrexate-based GVHD prophylaxis and a gender mis-
matched HCT (ie, male recipient from female donor versus
other) were less frequent in the validation cohort. Among
CGVHD characteristics, the validation cohort HCT recipients
were less likely to be diagnosed early (<5 months) after HCT
and to have a serum bilirubin of >2 mg/dL.
When assigning risk groups, the proportion of patients
assigned to the lower risk groups (RG1 and RG2) were
signiﬁcantly higher in the validation cohort compared with
the training cohort (Table 1). Surprisingly, in the validation
cohort, there were only 4 patients with a score value of 10
and none with a score value over 10. Because only 12% of the
patients (11% in RG3 and 1% in RG4) were assigned RG3 or
RG4, for testing the risk score, RG3 and RG4 were combined;
hence, only 3 categories were tested: RG1, RG2, and RG3.
Table 3 displays the distribution of risk score variables
Table 1
Characteristic of the Validation and Training Cohorts Including the 10
Variables Used to Build the CIBMTR Risk Score [18]
Characteristics Overall
Risk
Score*
Validation
Cohort
n (%)
Training
Cohort
n (%)
P
No. of patients 1128 5343
Variables associated with both OS and NRM included in CIBMTR CGVHD
score [18]
1. Age at transplantation, yr <.01
29 0 402 (36) 2022 (38)
30-59 1 594 (53) 3161 (59)
60 2 132 (12) 160 (3)
2. Donor-recipient gender pair <.01
Female to male 1 222 (20) 1378 (26)
Other combination 0 906 (80) 3965 (74)
3. Donor-recipient HLA match <.01
Identical sibling/well- or
partially-matched URD
0 1006 (89) 4289 (80)
Other related/mismatched
URD
1 122 (11) 758 (14)
4. Disease status at
transplantation
<.01
Early 0 900 (80) 2956 (55)
Intermediate 1 39 (3) 1367 (26)
Advanced 3 189 (17) 1020 (19)
5. GVHD prophylaxis regimen <.01
Cyclosporine 
methotrexate  other
0 391 (35) 3341 (63)
Tacrolimus  methotrexate
 other or T depletion
1 737 (65) 2002 (37)
6. Prior acute GVHD .61
No 0 311 (28) 1433 (27)
Yes 1 817 (72) 3910 (73)
7. Time from transplantation
to CGVHD onset
<.01
5 Months 0 550 (49) 2317 (43)
<5 Months 1 578 (51) 3026 (57)
8. KPS at the time of CGVHD
onset
<.01
80% 0 714 (63) 3007 (56)
<80% 1 414 (37) 1570 (29)
9. Total bilirubin at CGVHD
onset
<.01
<2 mg/dL 0 1059 (94) 3910 (73)
2 mg/dL 1 69 (6) 925 (17)
10. Platelet count at time of
CGVHD onset
.48
100  109/L 0 735 (65) 2650 (50)
<100  109/L 1 393 (35) 1921 (36)
Risk Groupy Overall Scorey Proportion of Patients
Validation Cohort Training Cohort
1 0-2 15 2.5
2 3-6 73 48
3 7-8 11 18
4 9-10 1 28
5 11 0 2.5
6 12 0 1
OS indicates overall survival.
* Disease risk status is categorized as follows: Early indicates acute my-
elogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) and in
ﬁrst complete remission (CR), chronic myelogenous leukemia (CML) in ﬁrst
chronic phase, and myelodysplastic syndrome (MDS) (refractory anemia
[RA] or RA with ringed sideroblasts). Intermediate indicates AML/ALL
(CR2), CML in accelerated phase or CP  2. Advanced indicates AML/ALL
(relapse or primary induction failure, CML in blast phase, MDS (RA with
excess of blast or in transformation).
y Risk group represents the sum of overall risk score assigned to each of the
above 10 variables associated with both NRM and OS in the Cox model as
previously described [18]. In the validation study, there were only 4 patients
with a score value of 10 and no patient with an overall score value above 10.
Table 2
Other Characteristics of the Validation and Training Cohorts [18] Not
Included in the 10 Variables
Characteristic Proportion of Patients P Value
Validation
Cohort
(n ¼ 1128)
Training
Cohort
(n ¼ 5343)
Year of transplantation 2005-2007 1995-2004
Age, median (range), yr 41 (<1-74) 36 (<1-72) <.01
Diagnosis at transplantation <.01
AML 53% 34%
ALL 27% 21%
CML 10% 34%
MDS 10% 11%
CMV serological status
before transplantation
.79
Donor and recipient
seronegative
28% 29%
Donor and recipient
seropositive
67% 66%
Missing 5% 5%
Graft source <.01
Bone marrow 25% 62%
Peripheral blood
stem cells
67% 36%
Umbilical cord blood 8% 2%
Conditioning regimen
intensity
<.01
Myeloablative 66% 89%
Type of CGVHD onset <.01
Progressive 28% 43%
Interrupted 40% 27%
De novo 28% 27%
Missing/not collected
on prior forms
4% 3%
Maximum grade of
chronic GVHD
<.01
Extensive 73% 68%
Limited 27% 32%
Follow-up of survivors,
median (range), mo*
63 (2-92) 73 (3-168) <.01
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; CMV, cytomegalovirus.
* Follow-up is deﬁned from date of CGVHD onset to date of last contact at
the time of the analysis.
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common variables among patients assigned to RG1 (>20% of
patients belonged to this category) were prior acute GVHD,GVHD prophylaxis other than CSA þ methotrexate  other,
and age > 29 years. Among patients assigned to RG2, in
addition to the above variables, shorter time from trans-
plantation to CGVHD and thrombocytopenia were also
frequent. Among patients assigned to RG3 or RG4, all vari-
ables except other related and mismatched URD and KPS <
80 were seen at a higher frequency.
Among other characteristics not included in building the
CGVHD risk score (Table 2), patients in the validation cohort
less frequently underwent transplantation for chronic mye-
logenous leukemia, had a higher proportion of patients
receiving peripheral blood stem cells or umbilical cord blood
as the stem cell graft source, and had higher proportion of
patients receiving an NMA or RIC regimen. Among CGVHD
characteristics, progressive onset was less frequent
compared with the training cohort (Table 2).
We tested the discriminatory ability of the risk score to
predict overall survival and NRM. Figure 1 shows the cu-
mulative incidence of overall survival and NRM according to
CGVHD risk groups. The probability of overall survival in RG1
was 72% (95% CI, 64% to 79%), RG2 was 53% (95% CI, 50% to
57%), and RG3 was 25% (95% CI, 18% to 33%) at 5 years after
the diagnosis of CGVHD. The cumulative incidence of NRM
was 17% (95% CI, 11% to 23%) in RG1, 26% (95% CI, 23% to 29%)
Table 4
Variables Independently Predictive of NRM in the Validation
CohortdResults of the Multivariable Analysis
Variable RR (95% CI) P Value Overall
P Value
n
RG score
1 1 <.0001 165
2 1.67 (1.10-2.54) .0155 824
3 3.98 (2.50-6.35) <.0001 139
CMV status before
transplantation
Donor/recipient
seronegative
1 .018 319
Others combination 1.39 (1.06-1.83) .018 809
Chronic GVHD onset
Progressive 1 .002 313
Interrupted .62 (.48-.82) .0006 448
De novo .54 (.40-.74) .0001 313
Missing .56 (.31-.99) .0477 54
Contrast
Risk group 2 versus
3 and 4
.42 (.32-.56) <.0001
Interrupted versus
de novo
1.14 (.83-1.57) .4102
Table 3
Comparison of Risk Score Characteristics between Assigned Risk Groups
Characteristics cGVHD CIBMTR Risk Group
1 2 3
No. of patients 165 824 139
Age at transplantation, yr
29 122 (74) 263 (32) 17 (12)
30-59 43 (26) 472 (57) 79 (57)
60 0 89 (11) 43 (31)
Disease risk at transplantation
Early 163 (99) 689 (84) 48 (35)
Intermediate 2 (1) 33 (4) 4 (3)
Advanced 0 102 (12) 87 (63)
Donor-recipient HLA match
Identical sibling/well- or
partially-matched URD
154 (93) 736 (89) 116 (83)
Other related/mismatched URD 11 (7) 88 (11) 23 (17)
Donor/recipient gender pair
Female to male 12 (7) 168 (20) 42 (30)
Other combinations 153 (93) 656 (80) 97 (70)
GVHD prophylaxis
Cyclosporine 
methotrexate  other
130 (79) 243 (29) 18 (13)
Tacrolimus  methotrexate
 other/T cell depletion
35 (21) 581 (71) 121 (87)
Prior acute GVHD
Yes 119 (72) 585 (71) 113 (81)
No 46 (28) 239 (29) 26 (19)
Time from transplantation to chronic GVHD diagnosis
<5 mo 22 (13) 446 (54) 110 (79)
5 mo 143 (87) 378 (46) 29 (21)
Platelet count at cGVHD onset,  109/L
<100 6 (4) 287 (35) 100 (72)
100 159 (96) 537 (65) 39 (28)
Total serum bilirubin at cGVHD onset, mg/dL
2 0 36 (4) 33 (24)
<2 165 (100) 788 (96) 106 (76)
KPS at cGVHD onset
<80 7 (4) 305 (37) 102 (73)
80 158 (96) 519 (63) 37 (27)
Follow-up of survivors,
median (range), mo*
62 (2-73) 64 (3-92) 63 (4-71)
* Follow-up is measured from onset of CGVHD.
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diagnosis of CGVHD, validating the predictive ability of the
risk score in predicting both overall survival and NRM.
In multiple regression analysis of NRM (Table 4), after
adjusting for cytomegalovirus serostatus and type of CGVHD
onset, the risk group was independently associated with
NRM (overall P < .0001). Relative risk (RR) of NRM was 1.67
(95% CI, 1.1 to 2.54; P ¼ .015) and 3.98 (95% CI, 2.5 to 6.35;
P < .0001) times higher in RG2 and RG3, respectively,
compared with RG1. Pairwise comparison also revealedFigure 1. Overall Survival (A) and NRM (B) among patients with CGVHD accordinglower RR of NRM in RG2 compared with RG3 (RR, .42; 95% CI,
.32 to .56; P < .0001), demonstrating the ability of the score
to differentiate all 3 levels of risk group from each another.
In multiple regression analysis of overall survival
(Table 5), after adjusting for disease and type of CGVHD
onset, the risk group was independently associated with
overall mortality (overall P< .0001). The RR of deathwas 1.87
(95% CI, 1.37 to 2.55; P< .0001) and 4.57 (95% CI, 3.18 to 6.58;
P < .0001) times in RG2 and RG3 compared with RG1. Pair-
wise comparison revealed lower RR of overall mortality in
RG2 compared with RG3 (RR, .41; 95% CI, .32 to .52; P <
.0001), conﬁrming the discriminative ability of the score to
stratify the 3 levels of risk groups from each another.
Although disease relapse was not the focus of the study,
the CGVHD score was evaluated and had no association with
risk of relapse in the validation cohort (data not shown).DISCUSSION
Results of the current analysis validated the original
CIBMTR risk score in predicting differences in overall survival
and NRM in an independent and more contemporaneous
cohort of patients with CGVHD. In contrast to our training
cohort, some difference was observed in applying the risk
score to validation cohort of patients. For instance, the pro-
portion of patients in the validation cohort assigned to RG4
to RG6 was very low, because only 4 patients (1%) had anto risk score. All estimates are estimated from the date of onset of CGVHD.
Table 5
Variables Independently Predictive of Overall Survival in the Validation
CohortdResults of the Multivariable Analysis
Variable RR (95% CI) P Value Overall
P Value
n
RG score
1 1 <.0001 165
2 1.87 (1.37-2.55) <.0001 824
3 4.57 (3.18-6.58) <.0001 139
Disease
AML 1 .0001 599
ALL .93 (.75-1.14) .4552 301
CML .66 (.48-.91) .0111 115
MDS .508 (.37-.71) <.0001 113
Chronic GVHD onset
Progressive 1 .002 313
Interrupted .78 (.64-.96) .0183 448
De novo .71 (.56-.89) .0031 313
Missing .48 (.29-.79) .0038 54
Contrast
RG 2 versus 3 and 4 .41 (.32-.52) <.0001
ALL versus CML 1.41 (.995-1.99) .0533
ALL versus MDS 1.82 (1.28-2.60) .0009
CML versus MDS 1.30 (.84-2.00) .2416
Interrupted versus
de novo
1.11 (.89-1.39) .3634
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score above 10, as compared with training cohort [18]
(Table 1). When evaluating the differences among the vari-
ables used to build the risk score between the 2 cohorts, the
baseline characteristics of the 2 populations are uniquely
different and appear mostly responsible for higher risk
scores in the training cohort (Table 3). Though the current
cohort had a higher proportion of older patients and patients
receiving GVHD prophylaxis with agents other than CSA þ
methotrexate  other, they had less frequent HCT from a
mismatched or other related donor, HCT in intermediate or
advanced disease status, and gender mismatched HCT.
CGVHD characteristics revealed that early diagnosis and
higher bilirubin were also less frequent. Although the rea-
sons for the very low proportion of patients assigned to RG4
to RG6 is not completely understood, similar ﬁndings have
been reported recently in a study that analyzed the CIBMTR
risk score in patients with chronic GVHD using the NIH
criteria at 2 individual centers [26]. In the Inamoto, Kim et al.
study, the proportion of patient represented in the RG4 was
only 1% and 0% representation for the RG5 and RG6, which
are similar to the ﬁndings or our validation cohort.
The disease groups selected in this study population
reﬂect the training cohort selection criteria. Applicability of
the risk score in nonmalignant diseases, particularly in
pediatric patients has not been tested.
ThoughCGVHDclassiﬁcationusingNIHconsensus criteria is
not available in the CIBMTR data base, the validation cohort
includespatientswithNIHchronicGVHDdiagnosis,whichmay
account for less frequent diagnosis of early CGVHD (persistent
or late acute misclassiﬁed as CGVHD) [16,27,28]. Despite this,
we observed good discriminatory ability of the risk score in
predicting survival andNRM.Moreover, asmentioned above, in
the study by Inamoto et al. [26], the application of the CIBMTR
risk score performed well in predicting differences in overall
survival also in contemporary patients treated for NIH-deﬁned
CGVHD (Supplemental Figure 1).
We also compared overall survival and NRM within the
respective RG, between the 2 cohorts (data not shown). Pa-
tients in the validation cohort had a lower probability of
overall survival at 5 years after the diagnosis of CGVHDcompared with the training cohort, within the 3/4 levels of
RG (90.8% versus 72% in RG1, 67.1% versus 53% in RG2, and
50.5 (RG3) and 40.2% (RG4) versus 25% (RG3) in the training
and validation cohorts, respectively). The cumulative inci-
dence of NRM was similarly lower in the training cohort for
RG1 (4.6% versus 17%), RG2 (20.4% versus 26%), and RG3
(33.2% in the training cohort), RG4 (43.2% in the training
cohort) versus 44% (RG3, in the validation cohort). This could
be accounted for by the fact that patients in the validation
cohort were signiﬁcantly older, accounting for the higher
mortality within the early RGs. Also, differences in the cohort
among variables not contributing to the risk score (Table 2),
but predictive of NRM and overall survival (Tables 4 and 5),
such as a higher proportion of patients with acute myeloid
leukemia and a lower proportion with CML in the validation
cohort, may account for the differences seen.
Prior studies have identiﬁed several factors predicting
overall survival and NRM, including thrombocytopenia,
greater than 50% skin involvement, lower gastrointestinal
involvement, progressive onset of CGVHD, HLA mismatch,
hyperbilirubinemia, lower KPS, and increasing age in
patients with CGVHD diagnosed by the traditional criteria
[2-17]. Single-institution retrospective studies have also
identiﬁed similar risk factors predicting major outcomes in
patients with CGVHD using the NIH criteria [16,17,27,28].
Among several prospective studies using NIH consensus
criteria, results from the CGVHD consortium reported similar
risk factors predicting overall survival and NRM, such as
thrombocytopenia and KPS of <80, but also identiﬁed new
factors, such as NIH overlap subtype of CGVHD and severe
NIH global severity [29].
A recent analysis through the CGVHD consortium reported
no impact of prior acute GVHD on overall survival or NRM
after CGVHD [30]. This is in contrast to our current report and
may reﬂect differences in the population as identiﬁed by the
NIH consensus criteria, excluding patients with late acute,
persistent, or recurrent acute GVHD. Also, the follow-up of the
consortium study is shorter at approximately 20 months
compared with 63 months in the current study.
As indicated above, a recent analysis applied the CIBMTR
risk score to NIH CGVHD including a cohort of 376 patients
treated at 2 individual centers [26]. Overall survival was well
stratiﬁed according to the risk score at both centers, and
NRM was stratiﬁed according to risk score at 1 center, con-
ﬁrming that the CIBMTR risk score performs well in pre-
dicting differences in overall survival in contemporary
patients treated for NIH CGVHD. Factors accounting for the
center-speciﬁc difference in mortality and the CIBMTR
cohort, particularly for patients in RG3, remains to be
determined (Supplemental Figure 1). A dedicated long-term
follow-up program may have contributed to the better sur-
vival of patients in this high-risk category. Supporting this
hypothesis, a recent CIBMTR survey found superior survival
for patients who underwent transplantation at centers that
have reported having a dedicated long-term follow-up clinic
(Navneet Majhail, personal communication).
To conclude, our study validates the prognostic value of
the CIBMTR CGVHD RGs for overall survival and NRM in a
recent transplantation population. The CIBMTR CGVHD RGs
can be used for prediction of major outcomes, treatment
planning, and enrollment in clinical trials.
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